Effect of Moristerol (anti-cholesterolemic agent) on benign prostatic hypertrophy
-
- Tajima, Atsushi
- The Department of Urology, Hamamatsu University School of Medicine
-
- Ohmi, Yoshio
- The Department of Urology, Social Insurance Hamamatsu Hospital
-
- Aso, Yoshio
- The Department of Urology, Iwata City Hospital
-
- Ohta, Nobutaka
- The Department of Urology, National Shizuoka Hospital
-
- Ushiyama, Tomomi
- The Department of Urology, Ensyu General Hospital
-
- Hata, Masahiro
- The Department of Urology, National Tenryu Hospital
Bibliographic Information
- Other Title
-
- 前立腺肥大症に対する脂質代謝改善剤モリステロールの効果
- ゼンリツセン ヒダイショウ ニ タイスル シシツ タイシャ カイゼンザイ モリ
Search this article
Abstract
Moristerol was orally administered in 20 cases of benign prostatic hypertrophy. One capsule of Moristerol contained 200 mg of soysterol . In all the cases, 9 capsules of Moristerol were given per day in three divided doses for 6 weeks. Clinical improvement was observed in 11 of the 20 cases (55%). It consisted mainly of subjective complaints such as improvement of dysuria, narrow and weak urinary stream and feeling of incomplete voiding. As objective findings, a statistically significant decrease of residual urine volume was noted after treatment, although shrinkage of the enlarged prostate was not clear upon palpation or roentgenography. In addition to the improvement of symptoms, serum lipid peroxide which might be considered to be a provocative cause of benign prostatic hypertrophy, was also significantly decreased by Moristerol administration. No marked side effects were seen in this study.
Journal
-
- Hinyokika Kiyo
-
Hinyokika Kiyo 29 (3), 365-369, 1983-03
泌尿器科紀要刊行会
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1050282677041617664
-
- NII Article ID
- 120002160440
-
- NII Book ID
- AN00208315
-
- ISSN
- 00181994
-
- HANDLE
- 2433/120129
-
- NDL BIB ID
- 2627286
-
- Text Lang
- ja
-
- Article Type
- departmental bulletin paper
-
- Data Source
-
- IRDB
- NDL
- CiNii Articles